Adropin and MOTS-c as new peptides: Do levels change in neurodegenerative diseases and ischemic stroke?

Simple item page
dc.contributor.authorSaçmacı H.
dc.contributor.authorÇakır M.
dc.contributor.authorÖzcan S.S.
dc.date.accessioned2024-07-22T08:03:10Z
dc.date.available2024-07-22T08:03:10Z
dc.date.issued2023
dc.description.abstractBackground: Neurological diseases such as Alzheimer's disease and Parkinson's disease (AD, PD), acute ischemic stroke (AIS), and multiple sclerosis (MS) are thought to be deeply affected by changes in the pathophysiological processes of neurons. As new peptides, it was aimed to evaluate the level of adropin and MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) and its possible relationship with NSE (neuron-specific enolase) and NF-L (neurofilament light chain) in terms of neuronal interaction. Methods: This study was conducted with 32 patients from each subgroup and group-appropriate controls. Disease identifiers and hemogram/biochemical parameters specific to the groups of participants were obtained. Additionally, plasma adropin, MOTS-c, NSE, and NF-L levels were evaluated by the ELISA method. Results: Plasma adropin levels were decreased in the AD group and decreased in MOTS-c, AIS, and AD groups compared to the control (p < 0.05). Similar values were found in the MS group compared to its control (p > 0.05). In correlation analysis of these markers with laboratory parameters, while platelet and cholesterol levels were negatively correlated with adropin levels; platelet, lymphocyte, and triglyceride levels were positively correlated with MOTS-c (p < 0.05). Conclusion: This study provides new information about adropin may be potentially important markers in AD and MOTS-C in AIS and AD. Future studies are needed to examine the relationship between changes in metabolic profiles and these peptides. © 2022 Wiley Periodicals LLC.
dc.identifier.DOI-ID10.1002/jbt.23246
dc.identifier.issn10956670
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12161
dc.language.isoEnglish
dc.publisherJohn Wiley and Sons Inc
dc.subjectHumans
dc.subjectIschemic Stroke
dc.subjectNeurodegenerative Diseases
dc.subjectPeptides
dc.subjectTranscription Factors
dc.subjectadropin
dc.subjectalanine aminotransferase
dc.subjectaspartate aminotransferase
dc.subjectcholesterol
dc.subjectcreatinine
dc.subjecthemoglobin
dc.subjecthigh density lipoprotein
dc.subjectmitochondrial protein
dc.subjectribosome RNA
dc.subjectthyrotropin
dc.subjecttriacylglycerol
dc.subjectunclassified drug
dc.subjectpeptide
dc.subjecttranscription factor
dc.subjectacute ischemic stroke
dc.subjectadult
dc.subjectalanine aminotransferase blood level
dc.subjectAlzheimer disease
dc.subjectArticle
dc.subjectaspartate aminotransferase blood level
dc.subjectcerebrovascular accident
dc.subjectcholesterol blood level
dc.subjectclinical article
dc.subjectcomorbidity
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectcreatinine blood level
dc.subjectcross-sectional study
dc.subjectdegenerative disease
dc.subjectdemography
dc.subjectdiffusion weighted imaging
dc.subjectdisease duration
dc.subjectenzyme linked immunosorbent assay
dc.subjectExpanded Disability Status Scale
dc.subjectfemale
dc.subjecthemoglobin blood level
dc.subjecthuman
dc.subjecthuman cell
dc.subjecthuman tissue
dc.subjectischemic stroke
dc.subjectleukocyte
dc.subjectleukocyte count
dc.subjectlymphocyte
dc.subjectmale
dc.subjectMini Mental State Examination
dc.subjectmultiple sclerosis
dc.subjectopen reading frame
dc.subjectParkinson disease
dc.subjectthrombocyte
dc.subjectthyrotropin blood level
dc.subjecttriacylglycerol blood level
dc.subjecturea nitrogen blood level
dc.subjectbrain ischemia
dc.titleAdropin and MOTS-c as new peptides: Do levels change in neurodegenerative diseases and ischemic stroke?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu